Bepreve - (1.5% ; Solution/Drops, Opthalmic)

Generic Name	Bepotastine Besilate	**Innovator**	BAUSCH AND LOMB INC
Dosage	1.5% ; Solution/Drops, Opthalmic	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Bepreve™ is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.